Tonix Pharmaceuticals has filed a registration statement to sell up to $500 million in securities. The company's lead drug candidate is for the management of fibromyalgia pain.
Let's delve into the US markets on Friday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
In his role at Celgene Corp, Hand played a strategic role in transactions including the $74 billion acquisition of Celgene by Bristol Myers Squibb and its subsequent integration.
Shares of Tonix Pharmaceuticals are pulling back 12.7% during Thursday's session. The stock is pulling back following a regulatory update on its experimental fibromyalgia treatment, TNX-102 SL.
Two biotech companies have surged on recent developments, illustrating biotech's volatility and prompting investors to evaluate potential long-term value.
Tonix Pharmaceuticals shares are trading higher by 22.5% during Monday's session. The company announced that the FDA will not require an Advisory Committee meeting for its New Drug Application for TNX-102 SL.
Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.
Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top gainers and losers in today's session.
